Tokyo-based Terumo Corp. has agreed to acquire Sequent Medical Inc. for $280 million and up to $100 million in commercial milestones, in a bid to get its hands on the CE-marked Web system for the treatment of cerebral aneurysms. Terumo plans to bring the system to the U.S. market following the completion of its ongoing pivotal trial for FDA approval.

WASHINGTON – Former Advamed CEO Stephen Ubl discussed the need to create a sound regulatory and reimbursement environment for personalized medications in his new role as the head of the Pharmaceutical Research and Manufacturers of America (PhRMA), during a keynote at last week’s conference sponsored by the Personalized Medicine Coalition.

WASHINGTON – Former Advamed CEO Stephen Ubl discussed the need to create a sound regulatory and reimbursement environment for personalized medications in his new role as the head of PhRMA, the main trade group representing the pharmaceutical industry. The May 25 keynote address occurred in downtown Washington at an annual conference sponsored by the Personalized Medicine Coalition.